Convalescent Plasma Therapy in Late-State, Severe COVID-19 Infection

被引:1
作者
Kumar, Neil R. [1 ]
Karanam, Veena C. [2 ]
Kumar, Shari [3 ]
Kumar, Sunil D. [4 ,5 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Internal Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Miami, FL USA
[3] Columbia Univ, Coll Dent Med, New York, NY USA
[4] Broward Hlth Med Ctr, Pulm Crit Care, Ft Lauderdale, FL 33316 USA
[5] Broward Hlth Med Ctr, 1600 S Andrews Ave, Ft Lauderdale, FL 33316 USA
关键词
convalescent plasma; COVID-19; severe; late stage; life threatening;
D O I
10.14423/SMJ.0000000000001546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesCurrent evidence favors plasma to be effective against coronavirus disease 2019 (COVID-19) in critically ill patients in the early stages of infection. We investigated the safety and efficacy of convalescent plasma in specifically late-stage (designated as after 2 weeks of hospital admission) severe COVID-19 infection. We also conducted a literature review on the late-stage use of plasma in COVID-19.MethodsThis case series examined eight COVID-19 patients admitted to the intensive care unit (ICU) who met criteria for severe or life-threatening complications. Each patient received one dose (200 mL) of plasma. Clinical information was gathered in intervals of 1 day pretransfusion and 1 hour, 3 days, and 7 days posttransfusion. The primary outcome was effectiveness of plasma transfusion, measured by clinical improvement, laboratory parameters, and all-cause mortality.ResultsEight ICU patients received plasma late in the course of COVID-19 infection, on average at 16.13 days postadmission. On the day before transfusion, the averaged initial Sequential Organ Failure Assessment (SOFA) score, PaO2:FiO(2) ratio, Glasgow Coma Scale (GCS), and lymphocyte count were 6.5, 228.03, 8.63, and 1.19, respectively. Three days after plasma treatment, the group averages for the SOFA score (4.86), PaO2:FiO(2) ratio (302.73), GCS (9.29), and lymphocyte count (1.75) improved. Although the mean GCS improved to 10.14 by posttransfusion day 7, the other means marginally worsened with an SOFA score of 5.43, a PaO2:FiO(2) ratio of 280.44, and a lymphocyte count of 1.71. Clinical improvement was noted in six patients who were discharged from the ICU.ConclusionsThis case series provides evidence that convalescent plasma may be safe and effective in late-stage, severe COVID-19 infection. Results showed clinical improvement posttransfusion as well as decreased all-cause mortality in comparison to pretransfusion predicted mortality. Randomized controlled trials are needed to conclusively determine benefits, dosage, and timing of treatment.
引用
收藏
页码:427 / 433
页数:7
相关论文
共 50 条
  • [21] Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study
    Ghadami, Ladan
    Hasibi, Mehrdad
    Asadollahi-Amin, Ali
    Asanjarani, Behzad
    Farahmand, Mohammad
    Abdollahi, Hamed
    MICROBIAL PATHOGENESIS, 2022, 165
  • [22] Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19
    Raturi, Manish
    Kala, Mansi
    Das, Kunal
    Kusum, Anuradha
    JOURNAL OF LABORATORY PHYSICIANS, 2021, 13 (01) : 91 - 94
  • [23] Convalescent plasma therapy in the treatment of COVID-19: Practical considerations
    Islam, Amin
    Rafiq, Shafquat
    Karim, Sabina
    Laher, Ismail
    Rashid, Harunor
    INTERNATIONAL JOURNAL OF SURGERY, 2020, 79 : 204 - 205
  • [24] COVID-19 convalescent plasma composition and immunological effects in severe patients
    Acosta-Ampudia, Yeny
    Monsalve, Diana M.
    Rojas, Manuel
    Rodriguez, Yhojan
    Esteban Gallo, Juan
    Carlos Salazar-Uribe, Juan
    Jose Santander, Maria
    Cala, Monica P.
    Zapata, Wildeman
    Isabel Zapata, Maria
    Manrique, Ruben
    Mauricio Pardo-Oviedo, Juan
    Camacho, Bernardo
    Ramirez-Santana, Carolina
    Anaya, Juan-Manuel
    JOURNAL OF AUTOIMMUNITY, 2021, 118
  • [25] Use of convalescent plasma in COVID-19
    David Macedo-Reynada, J.
    Ventura-Enriquez, Yanet
    GACETA MEDICA DE MEXICO, 2021, 157 : 68 - 78
  • [26] Effect of convalescent plasma in the treatment of severe acute respiratory distress syndrome caused by COVID-19 infection
    Lukic-Sarkanovic, Mirka
    Vico-Katanic, Nina
    Jerkovic, Milica
    Joksic-Mazinjanin, Radojka
    Terzic, Neda
    Zdravkovic, Ranko
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2024, 152 (5-6) : 238 - 243
  • [27] Convalescent plasma for COVID-19 considerations
    Pawitan, Jeanne Adiwinata
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (01)
  • [28] International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection
    Murphy, Michael
    Estcourt, Lise
    Grant-Casey, John
    Dzik, Sunny
    TRANSFUSION MEDICINE REVIEWS, 2020, 34 (03) : 151 - 157
  • [29] Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection
    Escobedo-Sanchez, Priscila Edith
    de la Cruz-Hernandez, Ibis
    Ramos-Garcia, Meztli
    Sanchez-Yedra, Ivan
    Garcia-Vazquez, Carlos
    Guzman-Priego, Crystell Guadalupe
    Garcia-Vidrios, Maria Victoria
    Olvera-Hernandez, Viridiana
    Mendoza-Garcia, Yolanda
    Ble-Castillo, Jorge Luis
    MEDICINA CLINICA, 2023, 161 (08): : 323 - 329
  • [30] Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome *
    Allahyari, Abolghasem
    Seddigh-Shamsi, Mohsen
    Mahmoudi, Mahmoud
    Jamehdar, Saeid Amel
    Amini, Mahnaz
    Mozdourian, Mahnaz
    Javidarabshahi, Zahra
    Abadi, Saeed Eslami Hasan
    Amini, Shahram
    Sedaghat, Alireza
    Emadzadeh, Maryam
    Nodeh, Mohammad Moeini
    Rahimi, Hossein
    Bari, Alireza
    Mozaheb, Zahra
    Kamandi, Mostafa
    Azimi, Sajad Ataei
    Abrishami, Mojtaba
    Akbarian, Arezoo
    Ataei, Parisa
    Allahyari, Negin
    Hasanzadeh, Sepideh
    Saeedian, Neda
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 93